Yu-wei Chen

Title(s)Assistant Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
Emailyuc209@ucsd.edu
ORCID ORCID Icon0000-0001-7988-319X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    National Cheng Kung University College of Medicine, Tainan, TaiwanMD01/2012
    Harvard T.H. Chan School of Public Health, Boston, MAMS06/2015Epidemiology
    Cleveland Clinic Foundation, Cleveland, OHInternal Medicine Residency06/2019
    Vanderbilt University Medical Center, Nashville, TNMedical Oncology Fellowship06/2022
    Vanderbilt University Medical Center, Nashville, TNGenitourinary Oncology Fellowship06/2023
    Collapse Awards and Honors
    ASCO Conquer Cancer Foundation2022  - 2023Young Investigator Award
    Vanderbilt University Medical Center2022  - 2023Carol O’Hare Endowed Genitourinary Oncology Fellowship Award
    ASCO Conquer Cancer Foundation2022Annual Meeting Abstract Merit Award
    ASCO/AACR2021Methods in Clinical Cancer Research Workshop Participant
    Vanderbilt University Medical Center2021  - 2022T32 Training Grant in Molecular and Genetic Epidemiology
    Cleveland Clinic2018Internal Medicine Residency Research Competition 1st Place Award Winner
    American Society of Hematology2017Abstract Achievement Award

    Collapse Overview 
    Collapse Overview
    I am a genitourinary (GU) medical oncologist at the Moores Cancer Center of UC San Diego Health. I treat and research on GU malignancies (prostate, kidney, bladder, and testicular cancer).

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Treatment Landscape of Renal Cell Carcinoma. Curr Treat Options Oncol. 2023 Dec; 24(12):1889-1916. Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR. PMID: 38153686; PMCID: PMC10781877.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Polygenic Risk Scores Associated with Tumor Immune Infiltration in Common Cancers. Cancers (Basel). 2022 Nov 14; 14(22). Choi J, Kim JS, Sung HJ, Chen YW, Chen Z, Wen W, Shu XO, Guo X. PMID: 36428664; PMCID: PMC9688863.
      View in: PubMed   Mentions: 1  
    3. Emerging Targets in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2022 Oct 04; 14(19). Chen YW, Rini BI, Beckermann KE. PMID: 36230766; PMCID: PMC9561986.
      View in: PubMed   Mentions: 9  
    4. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers (Basel). 2022 Aug 07; 14(15). Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann KE, Davis NB, Harrison MR, Kaiser EG, McAlister RK, Schaffer KR, Wallace DE, George DJ, Rathmell WK, Rini BI, Zhang T. PMID: 35954493; PMCID: PMC9367298.
      View in: PubMed   Mentions: 4  
    5. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Oncol Rep. 2022 06; 24(6):695-702. Chen YW, Rini BI. PMID: 35247142.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    6. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021 Nov 03; 9(1):80. Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, Rathmell WK, Rini BI, Zhang T. PMID: 34732251; PMCID: PMC8564988.
      View in: PubMed   Mentions: 13  
    7. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021 09; 155:291-293. Chen YW, Tucker MD, Beckermann KE, Iams WT, Rini BI, Johnson DB. PMID: 34400057; PMCID: PMC8316066.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    8. Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. Clin Genitourin Cancer. 2021 02; 19(1):e12-e16. Sheng IY, Wei W, Chen YW, Gilligan TD, Barata PC, Ornstein MC, Rini BI, Garcia JA. PMID: 32800474.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    9. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. Res Pract Thromb Haemost. 2019 Apr; 3(2):226-233. Kunapareddy G, Switzer B, Jain P, Conces M, Chen YW, Patel B, Patel S, Pinnamaneni P, Pohlman B, Angelini DE, McCrae KR, Khorana AA. PMID: 31011706; PMCID: PMC6462749.
      View in: PubMed   Mentions: 10  
    10. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. Urol Oncol. 2018 10; 36(10):470.e19-470.e29. Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, Garcia JA, Rini BI. PMID: 30131292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Prevalence of Venous Thromboembolism Diagnosed in Emergency Department Visits by Cancer Patients and Associated Healthcare Resource Utilization in the United States. Am J Hematol. 2018 May 23. Chen YW, Wang MJ, Khorana AA. PMID: 29790587.
      View in: PubMed   Mentions: 1     Fields:    
    12. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 29555248.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. PMID: 29231964.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    14. National Trends in Admission for Aspiration Pneumonia in the United States, 2002-2012. Ann Am Thorac Soc. 2017 Jun; 14(6):874-879. Wu CP, Chen YW, Wang MJ, Pinelis E. PMID: 28272915.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    15. The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm. Am J Hematol. 2017 Jun; 92(6):E101-E103. Chen YW, Khorana AA. PMID: 28263404.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. PMID: 28453693.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    17. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192. Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY. PMID: 28117383; PMCID: PMC5435968.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    18. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. PMID: 28462857.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Cost-effectiveness of Management Options for Small Renal Mass: A Systematic Review. Am J Clin Oncol. 2016 10; 39(5):484-90. Wang Y, Chen YW, Leow JJ, Levy AC, Chang SL, Gelpi FH. PMID: 27322701.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    20. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. PMID: 27528590.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):624-8. Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. PMID: 27681758.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    22. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. PMID: 27434225.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    23. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016 Nov - Dec; 15(6):701-706. Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. PMID: 27317191.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice? Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):313-317. Muralidhar V, Rose BS, Chen YW, Nezolosky MD, Nguyen PL. PMID: 27496390.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    25. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. PMID: 28723519.
      View in: PubMed   Mentions: 13     Fields:    
    26. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. PMID: 27059190.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. PMID: 26970022.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    28. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. PMID: 26972640.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    29. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22. Nezolosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 26476663.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32. Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 26391387.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. PMID: 26207642.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    32. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3. Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 26119229.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    33. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 25845283.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    34. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 25990612.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF, Nguyen PL. PMID: 25887342.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. PMID: 25681290.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    37. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. PMID: 24980272.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Yu-wei's Networks
    Concepts (138)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California